Fig. 5: Biological consequences after treatment of POEM/siSPB9 NPs. | Nature Communications

Fig. 5: Biological consequences after treatment of POEM/siSPB9 NPs.

From: Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance

Fig. 5

a Whole body imaging and quantification of luminous intensity of tumors of KPC-C2-Luc tumor-bearing C57BL/6 mice receiving intravenous administration of POEM/siLuc NPs once every 3 days. siCT refers to non-targeting siRNA as a control. n = 5 mice. b The mRNA expression levels of SPB9 in KPC-C2 tumors following various treatments three times. n = 5 mice. Changes of average tumor volumes (c) and individual tumor volume (d) in KPC-C2 WT tumor (subcutaneous)-bearing mice receiving various treatments. n = 5 mice. e The scheme for the establishment of pancreatic orthotopic model and treatments. Created in BioRender. Mu, Y. (2025) https://BioRender.com/wu7dxg8. Whole-body imaging (f) and luminous intensity of tumors (g) of KPC-C2-Luc tumor (orthotopic)-bearing mice following different treatments. n = 6 mice. h Survival rate of KPC-C2-Luc tumor (orthotopic)-bearing mice receiving various treatments. n = 6 mice. Data are presented as mean ± s.e.m. in (a–c, f, g). Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test for comparison in (b, d), two-way ANOVA with Tukey’s post hoc test for comparison in (a, c, g), and log rank test for comparison in (h). Source data are provided as a Source Data file.

Back to article page